Judy Mikovits Shocks The World: Most Damning Covid Evidence Bombshell The World Has Seen

June 17, 2022 admin Comments 0 Comment

Science and medicine have no other modern definition than FAKE at this point in time. Dr. Judy Mikovits presents her findings of medical fraud, and how Fauci was involved in her arrest AND career destruction.

Buy tickets to see Mikovits at the crimes against humanity conference: https://pathtotruth.ticketleap.com/t/Stewpeters/

CRIMES AGAINST HUMANITY TOUR USA: WITH PATRICK WOOD, DR. JUDY MIKOVITS & DR. REINER FUELLMICH

This paper is clearly not meant to be seen. I typed in the EXACT words of the title into Google/DuckDuckGo and had to go through all sorts of hoops – eventually I found it using the Russian Yandex search engine which is the only one that is not censored these days.

Retroviruses Pseudotyped with the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Efficiently Infect Cells Expressing Angiotensin-Converting Enzyme 2

September 2004
Journal of Virology 78(19):10628-10635

DOI:10.1128/JVI.78.19.10628-10635.2004

Infection of receptor-bearing cells by coronaviruses is mediated by their spike (S) proteins. The coronavirus (SARS-CoV) that causes severe acute respiratory syndrome (SARS) infects cells expressing the receptor angiotensin-converting enzyme 2 (ACE2). Here we show that codon optimization of the SARS-CoV S-protein gene substantially enhanced S-protein expression. We also found that two retroviruses, simian immunodeficiency virus (SIV) and murine leukemia virus, both expressing green fluorescent protein and pseudotyped with SARS-CoV S protein or S-protein variants, efficiently infected HEK293T cells stably expressing ACE2. Infection mediated by an S-protein variant whose cytoplasmic domain had been truncated and altered to include a fragment of the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein was, in both cases, substantially more efficient than that mediated by wild-type S protein. Using S-protein-pseudotyped SIV, we found that the enzymatic activity of ACE2 made no contribution to S-protein-mediated infection. Finally, we show that a soluble and catalytically inactive form of ACE2 potently blocked infection by S-protein-pseudotyped retrovirus and by SARS-CoV. These results permit studies of SARS-CoV entry inhibitors without the use of live virus and suggest a candidate therapy for SARS.